Baseline patients’ characteristics were similar between cohorts in both treatment armsTable 2.Among patients who received PEG-IFN-α2a, the mean age in the subject cohort ranged from 45 to 52 years of age; gender distribution ranged from 27 to 61% male; hard-to-treat HCV types of 1/4 ranged from 52 to 100%; viral load ranged from 570 ×103 to 3.1 × 106;, and the proportion of patients with cirrhosis ranged from 18 to 20%. Here, IFNA2 is linked to Cirrhosis.